Quick Takeaways
- GILEAD SCIENCES, INC. filed SCHEDULE 13D/A for Arcellx, Inc. Common Stock, par value $0.001 (ACLX).
- Disclosed ownership: 100%.
- Date of event: 28 Apr 2026.
GILEAD SCIENCES, INC. - 28 Apr 2026 SCHEDULE 13D/A Report for Arcellx, Inc. Common Stock, par value $0.001 (ACLX)
- Filing Manager
- GILEAD SCIENCES, INC.
- Reporting Manager
- GILEAD SCIENCES, INC.
- Symbol
- ACLX
- Shares outstanding
- 100 shares
- Disclosed Ownership
- 100 shares
- Ownership
- 100%
- Form type
- SCHEDULE 13D/A
- Filing time
- 28 Apr 2026, 09:13:16 UTC
- Date of event
- 28 Apr 2026
- Previous filing
- 23 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"GILEAD SCIENCES, INC. disclosed 100% ownership in Arcellx, Inc. Common Stock, par value $0.001 (ACLX) on 28 Apr 2026."
What Changed
- Previous schedule filing date: 23 Feb 2026.
- Current filing was accepted on 28 Apr 2026, 09:13.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 100% | 100 | 100 | 0 | /s/ Andrew D. Dickinson | Andrew D. Dickinson / Chief Financial Officer | 0000882095 |